Table 2.
Representative therapeutic studies targeting neutrophil in liver IRI
| Agent | Effect on Neutrophil | Reference |
|---|---|---|
| Anti-Ly6G mAb | Neutrophil depletion | Loi 2013 (many other) |
| Anti-Mac1 mAb | Inhibit neutrophil adhesion | Jaeschke 1993 |
| Anti-ICAM1 mAb | Inhibit neutrophil adhesion | Nakano 1995 |
| Peptide Bβ 15–42 | Inhibit neutrophil adhesion | Liu 2013 |
| CXCR2 antagonist | Inhibit neutrophil migration | de Oliveira 2017 |
| FPR1 antagonist | Inhibit neutrophil migration | Honda 2017 |
| Anti-MMP9 mAb | Inhibit ECM degradation | Hamada 2008 |
| Neutrophil erastase inhibitor | Inhibit neutrophil erastase | Uchida 2010 |
| Btk inhibitor | Limit neutrophil activation | Palumbo 2017 |
| gp91phox inhibitor | Reduce ROS generation | Kimura 2016 |
| PAD4 inhibitor | Reduce NETs | Huang 2015 |
| DNAse I | Reduce NETs | Huang 2015 |